生命科学资讯

US commission urges action as China's biotech sector advances

UK committee demands ‘much-needed clarity’ on UK-US pharma trade deal

Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths

Endpoints biopharma sentiment survey for Q1 2026

AI startup Edison raises $70M seed for research software

After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset

Biopharma's winners and losers of 2025

Takeda's $4B immunology drug achieves first Phase 3 successes

Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints

Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A

Atavistik raises $120M for bleeding disorder, blood cancer drugs

Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support

Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis

Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

European Commission unveils EU Biotech Act as it lags behind other countries

Senate passes Biosecure Act aimed at Chinese suppliers

RFK Jr. adds conditions to newborn screening list after committee termination

CDC stops recommending universal hepatitis B birthdose

Several companies expected to announce ‘most favored nation’ deals Friday at White House